HC Wainwright & Co. resumed coverage on Indaptus Therapeutics with a new price target

1/31/22 7:21:10 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

HC Wainwright & Co. resumed coverage of Indaptus Therapeutics with a rating of Buy and set a new price target of $15.00

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$INDP

Date	Price Target	Rating	Analyst
1/31/2022	$15.00	Buy	HC Wainwright & Co.
10/19/2021	$16.00	Hold → Buy	Maxim Group